An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)

  • Inam, Shafqat (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)
  • Lee, Denise (Chief Investigator (CI))

Project: Research

Project Details

StatusFinished
Effective start/end date22/12/22 → 21/12/24

Keywords

  • Clinical trial
  • Lymphoma
  • Epstein-Barr